These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The coagulation system as a target for the treatment of human gliomas. Ornstein DL; Meehan KR; Zacharski LR Semin Thromb Hemost; 2002 Feb; 28(1):19-28. PubMed ID: 11885022 [TBL] [Abstract][Full Text] [Related]
24. New anticoagulants and their potential impact on the treatment of thromboembolic disease. Ansell J Curr Hematol Rep; 2004 Sep; 3(5):357-62. PubMed ID: 15341703 [TBL] [Abstract][Full Text] [Related]
25. The rationale of anticoagulants in the treatment of cancer. Cliffton EE; Grossi CE J Med; 1974; 5(1):107-13. PubMed ID: 4275504 [No Abstract] [Full Text] [Related]
27. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Zikria JC; Ansell J Curr Opin Hematol; 2009 Sep; 16(5):347-56. PubMed ID: 19550318 [TBL] [Abstract][Full Text] [Related]
28. An update on new anticoagulants. Linkins LA; Weitz JI Curr Drug Targets Cardiovasc Haematol Disord; 2003 Dec; 3(4):287-300. PubMed ID: 14683471 [TBL] [Abstract][Full Text] [Related]
29. Antitumor and antimetastatic effect of warfarin and heparins. Bobek V; Kovarík J Biomed Pharmacother; 2004 May; 58(4):213-9. PubMed ID: 15183845 [TBL] [Abstract][Full Text] [Related]
30. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy. Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594 [TBL] [Abstract][Full Text] [Related]
31. Management of thrombosis in the cancer patient. Andrea N; Ansell J J Support Oncol; 2003; 1(4):235-8, 240-2; discussion 239-40, 243-5. PubMed ID: 15334865 [TBL] [Abstract][Full Text] [Related]
32. Current concepts for the prevention of venous thromboembolism. Bramlage P; Pittrow D; Kirch W Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142 [TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. Spyropoulos AC; Turpie AG; Dunn AS; Spandorfer J; Douketis J; Jacobson A; Frost FJ; J Thromb Haemost; 2006 Jun; 4(6):1246-52. PubMed ID: 16706967 [TBL] [Abstract][Full Text] [Related]
34. New anticoagulants. Bauer KA Curr Opin Hematol; 2008 Sep; 15(5):509-15. PubMed ID: 18695376 [TBL] [Abstract][Full Text] [Related]
36. A preliminary assessment of the critical differences between novel oral anticoagulants currently in development. McBride BF J Clin Pharmacol; 2005 Sep; 45(9):1004-17. PubMed ID: 16100294 [TBL] [Abstract][Full Text] [Related]
37. New anticoagulant therapy. Linkins LA; Weitz JI Annu Rev Med; 2005; 56():63-77. PubMed ID: 15660502 [TBL] [Abstract][Full Text] [Related]
38. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. Nishioka J; Goodin S J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108 [TBL] [Abstract][Full Text] [Related]
39. Initial treatment of venous thromboembolism. Becattini C; Agnelli G; Emmerich J; Bura A; Weitz JI Thromb Haemost; 2006 Sep; 96(3):242-50. PubMed ID: 16953263 [TBL] [Abstract][Full Text] [Related]